In the phase 3 SUBITO trial, researchers aimed to compare outcomes with intensified alkylating chemotherapy to those with an HRD-targeting regimen.

Mumbai: Alembic Pharmaceuticals Limited (Alembic) has announced that its Partner NATCO Pharma Limited (NATCO) has received ...

Patients with cancers that are driven by certain mutations occurring in response to DNA damage can be safely treated with two drugs, olaparib and adavosertib, if they are given in sequence rather than ...

The National Institute for Health and Care Excellence (NICE) has recommended the use of olaparib (Lynparza) for BRCA-mutated early breast cancer and hormone-relapsed metastatic prostate cancer ...

Natco Pharma receives USFDA approval for generic Olaparib tablets, partnering with Alembic Pharmaceuticals for distribution in the U.S.

Natco Pharma gets USFDA tentative approval for generic Olaparib tablets, a Lynparza equivalent. Sales hit $1.4B in US.

A phase 3 trial evaluating olaparib (Lynparza) against standard of care chemotherapy in women with HER2-negative metastatic breast cancer has seen significant improvement in progression-free survival ...

Interim findings from the DUO-O trial could signal new options for women diagnosed with ovarian cancer at later stages who do not have a BRCA mutation. Patients newly diagnosed with advanced ovarian ...

Australian researchers have shown for the first time that a new drug used to treat breast cancer patients damages the store of immature eggs in the ovaries of mice. Their research shows that olaparib ...

Researchers found that the common blood pressure drug telmisartan can significantly improve the performance of the cancer ...

CHICAGO — A few months ago, olaparib (Lynparza, AstraZeneca) was the first drug approved to treat women with advanced breast cancer with germline mutations in BRCA. That approval was based on a ...

"Precision drug olaparib may be effective without hormone therapy for some men with biochemically recurrent prostate cancer." ScienceDaily. www.sciencedaily.com / releases / 2024 / 08 / ...